Xian Janssen Pharmaceutical Ltd.

Xian Janssen Pharmaceutical Ltd. is described on its official website as a pharmaceutical subsidiary of Johnson & Johnson in China and one of the first foreign-funded pharmaceutical enterprises to enter China. It states that it has been bringing medicines to China since 1985 and focuses on research, introduction and production of medicines and innovative health solutions. Its products are described as focusing on six disease areas: oncology, immunology, infectious diseases and vaccines, neuroscience, cardiovascular and metabolism, and pulmonary hypertension.

According to the official website, Xian Janssen's history is connected to bringing the first batch of medicines to China in 1985, and the company describes itself as having been established in China since 1985. The official about page states that the founding of Xian Janssen began with Dr. Paul Janssen's love for China. The company overview page states that as one of the earliest multinational pharmaceutical companies and Johnson & Johnson's largest pharmaceutical subsidiary in China, it has been committed to research, introduction and production of high-quality medicines and innovative pharmaceutical solutions to meet China's growing medical and health needs. It also states that as of 2018 it had offices in 29 cities across China and nearly 3,000 employees.

• 2018

  Company reports offices in 29 cities across China and nearly 3,000 employees.

• 1985

  Xian Janssen brings its first medicines into China, marking the start of its operations in the country.

• China launch of Rybrevant (amivantamab injection, subcutaneous) in combination with Lazcluze.

• Approval in China of Icotyde (icotrokinra tablets), a targeted oral peptide, for plaque psoriasis.

• Approval in China of Tremfya (guselkumab) as the first interleukin-23 inhibitor for ulcerative colitis.

• Rybrevant (amivantamab injection, subcutaneous)

  Oncology therapy launched in China in combination with Lazcluze, described as offering a convenient and short first-line combination treatment option.

• Lazcluze

  Combination partner for Rybrevant in China.

• Icotyde (icotrokinra tablets)

  Targeted oral peptide approved in China for first-line systemic treatment of plaque psoriasis.

• Tremfya (guselkumab)

  Approved in China as the first interleukin-23 inhibitor for ulcerative colitis.

• 2011

  Source

Read more

1. 1首页 | 西安杨森制药有限公司xian-janssen.com.cn
2. 2关于我们 | 西安杨森制药有限公司xian-janssen.com.cn
3. 3公司概览 | 西安杨森制药有限公司xian-janssen.com.cn
4. 4Xian Janssen Pharmaceutical Ltd. (China) - Wikidatawikidata.org
5. 5“楷莱”“万珂”被药监局要求召回停售news.cntv.cn
6. 6“楷莱”“万珂”被药监局要求召回停售nbd.com.cn